Rozanolixizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Rozanolixizumab. Educational only — not medical advice.
Labeled uses
RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
Source: FDA labeling via NIH DailyMed (set 3c0eb8c2…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.